Spots Global Cancer Trial Database for Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Official Title: A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies

Study ID: NCT00975819

Conditions

Kaposiform Hemangioendotheliomas

Tufted Angioma

Capillary Venous Lymphatic Malformation

Venous Lymphatic Malformation

Microcystic Lymphatic Malformation

Mucocutaneous Lymphangiomatosis and Thrombocytopenia

Capillary Lymphatic Arterial Venous Malformations

PTEN Overgrowth Syndrome With Vascular Anomaly

Lymphangiectasia Syndromes

Interventions

sirolimus

Study Description

Brief Summary: The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved clinical status and quality of life. Funding Source - FDA OOPD (Food and Drug Administration - Office of Orphan Products Development)

Detailed Description: Patients with vascular anomalies (VA) have a spectrum of diseases that can be broadly classified into vascular tumors and malformations. Complicated vascular anomalies can cause disfigurement, chronic pain, and organ dysfunction with significant morbidity and mortality. Despite the severity of potential complications, we lack uniform guidelines for the treatment and response to treatment of children and young adults with these diseases. There are pre-clinical and clinical data supporting the essential regulatory function of the PI3K/Akt/mTOR pathway in vascular growth and organization, and suggest a therapeutic target for patients with complicated vascular anomalies. The overall goal of this trial is to objectively determine the effectiveness and safety of the mTOR inhibitor Rapamycin\* in the treatment of children and young adults diagnosed with complicated vascular anomalies. We propose a Phase 2 trial with the diagnostic, therapeutic and response criteria experimentally determined in this study used as a framework for future Phase 3 clinical trials.